These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33509156)
1. Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status. Gyaase S; Asante KP; Adeniji E; Boahen O; Cairns M; Owusu-Agyei S BMC Public Health; 2021 Jan; 21(1):240. PubMed ID: 33509156 [TBL] [Abstract][Full Text] [Related]
2. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. RTS,S Clinical Trials Partnership PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396 [TBL] [Abstract][Full Text] [Related]
4. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR; Malar J; 2011 Aug; 10():224. PubMed ID: 21816029 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. RTS,S Clinical Trials Partnership Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
10. The Advanced Development Pathway of the RTS,S/AS01 Vaccine. von Seidlein L Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502 [TBL] [Abstract][Full Text] [Related]
11. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768 [TBL] [Abstract][Full Text] [Related]
12. Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria. Bell GJ; Gyaase S; Goel V; Adu B; Mensah B; Essone P; Dosoo D; Osei M; Niare K; Wiru K; Brandt K; Emch M; Ghansah A; Asante KP; Mvalo T; Agnandji ST; Juliano JJ; Bailey JA BMC Infect Dis; 2023 Oct; 23(1):716. PubMed ID: 37872492 [TBL] [Abstract][Full Text] [Related]
13. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182 [TBL] [Abstract][Full Text] [Related]